Cardiovascular screening outcomes in the Dutch survivorship care program for Hodgkin lymphoma survivors
ConclusionsAdherence to the screening guidelines in the Dutch HL survivorship care program was reasonable to good and a substantial number of actionable (risk factors for) CVD were diagnosed.Implications for Cancer Survivors.Our findings inform HL survivors at high risk of late cardiotoxicity about cardiovascular screening findings and demonstrate appropriate therapeutic actions after diagnosis of (risk factors for) CVD. (Source: Journal of Cancer Survivorship)
Source: Journal of Cancer Survivorship - April 23, 2024 Category: Cancer & Oncology Source Type: research
Cancers, Vol. 16, Pages 1580: T-Cell Engagers & mdash;The Structure and Functional Principle and Application in Hematological Malignancies
Cancers, Vol. 16, Pages 1580: T-Cell Engagers—The Structure and Functional Principle and Application in Hematological Malignancies
Cancers doi: 10.3390/cancers16081580
Authors:
Paweł Cech
Katarzyna Skórka
Laura Dziki
Krzysztof Giannopoulos
Recent advancements in cancer immunotherapy have made directing the cellular immune response onto cancer cells a promising strategy for the treatment of hematological malignancies. The introduction of monoclonal antibody-based (mAbs) targeted therapy has significantly improved the prognosis for hematological patients. Facing the issues of mAb-based therapies, a ...
Source: Cancers - April 20, 2024 Category: Cancer & Oncology Authors: Pawe ł Cech Katarzyna Sk órka Laura Dziki Krzysztof Giannopoulos Tags: Review Source Type: research
A pilot randomized controlled trial of an online intervention for Hodgkin lymphoma survivors to increase knowledge about late effects and recommended screening
ConclusionOnline education modules for high-risk HL survivors are an acceptable method to improve knowledge of health risks and screening guidelines. Future interventions should focus on improving screening uptake in this population.Implications for Cancer SurvivorsWeb-based learning can be useful in increasing cancer survivor knowledge of their unique risks and screening recommendations but does not necessarily change patient behavior. Involvement in a cancer survivorship program can help assess individual barriers and monitor uptake of screening. (Source: Journal of Cancer Survivorship)
Source: Journal of Cancer Survivorship - April 20, 2024 Category: Cancer & Oncology Source Type: research
Editors ’ Picks
Cutaneous T-cell lymphomas (CTCLs) comprise an incurable form of non-Hodgkin lymphoma, and advanced-stage forms of this disease, mycosis fungoides and Sezary syndrome, have poor prognosis. Previous case series documented long-lasting remission due to a graft-versus-lymphoma effect in patients treated with allogeneic hematopoietic stem cell transplantation (HSCT). In these studies, lymphoma relapse was common, and treatment-related morbidity and mortality were noted, leading to weaker recommendations for HSCT in this patient population. (Source: Journal of Investigative Dermatology)
Source: Journal of Investigative Dermatology - April 19, 2024 Category: Dermatology Tags: Editors' Picks Source Type: research
Late-onset Familial Hemophagocytic Lymphohistiocytosis in a survivor of Hodgkin's Lymphoma
Leuk Res Rep. 2023 Nov 7;21:100394. doi: 10.1016/j.lrr.2023.100394. eCollection 2024.ABSTRACTHemophagocytic Lymphohistiocytosis is an inflammatory condition which results in over activation of the immune system. It could be either sporadic or familial. The familial subtype is linked with various genetic mutations and is commonly a disease of the young. Here we report a case of HLH in an adult, occurring in the background of a successfully treated hematological malignancy. Upon workup, he was also found to have pathogenic STXBP2 mutation, suggesting HLH of familial origin. To date, only few cases of adult-onset familial HLH...
Source: Cell Research - April 17, 2024 Category: Cytology Authors: Mirza Rameez Samar Daania Shoaib Nida E Zehra Munira Moosajee Source Type: research
Clinical characteristics and prognostic analysis of primary extranodal non-Hodgkin lymphoma of the head and neck
CONCLUSIONS: The most common site of PE-NHL in these Chinese patients was the Waldeyer's ring, but the incidence in the nasal cavity was higher than that reported in Western countries. Radiotherapy combined with chemotherapy had better efficacy than chemotherapy alone, and the prognosis depended on the ECOG score and clinical stage. IPI had a better prognostic value in patients in the high-risk group of head and neck PE-NHL.PMID:38604163 | DOI:10.18632/aging.205726 (Source: Aging)
Source: Aging - April 11, 2024 Category: Biomedical Science Authors: Jiamu Lv Yining Jiang Tingting Yu Shengrui Gao Wanzhong Yin Source Type: research
Clinical characteristics and prognostic analysis of primary extranodal non-Hodgkin lymphoma of the head and neck
CONCLUSIONS: The most common site of PE-NHL in these Chinese patients was the Waldeyer's ring, but the incidence in the nasal cavity was higher than that reported in Western countries. Radiotherapy combined with chemotherapy had better efficacy than chemotherapy alone, and the prognosis depended on the ECOG score and clinical stage. IPI had a better prognostic value in patients in the high-risk group of head and neck PE-NHL.PMID:38604163 | DOI:10.18632/aging.205726 (Source: Aging)
Source: Aging - April 11, 2024 Category: Biomedical Science Authors: Jiamu Lv Yining Jiang Tingting Yu Shengrui Gao Wanzhong Yin Source Type: research
Clinical characteristics and prognostic analysis of primary extranodal non-Hodgkin lymphoma of the head and neck
CONCLUSIONS: The most common site of PE-NHL in these Chinese patients was the Waldeyer's ring, but the incidence in the nasal cavity was higher than that reported in Western countries. Radiotherapy combined with chemotherapy had better efficacy than chemotherapy alone, and the prognosis depended on the ECOG score and clinical stage. IPI had a better prognostic value in patients in the high-risk group of head and neck PE-NHL.PMID:38604163 | DOI:10.18632/aging.205726 (Source: Aging)
Source: Aging - April 11, 2024 Category: Biomedical Science Authors: Jiamu Lv Yining Jiang Tingting Yu Shengrui Gao Wanzhong Yin Source Type: research
FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL)
This study evaluates the role of fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) in NHL treated with CAR T-cell therapy concerning response assessment and prognosis.We evaluated 34 patients with NHL who received a CAR T-cell therapy between August 2019 and July 2022. All patients underwent a pre-therapeutic FDG-PET/CT (PET-0) 6 days prior and a post-therapeutic FDG-PET/CT (PET-1) 34 days after CAR T-cell therapy. Deauville score (DS) was used for evaluation of response to therapy and compared to a minimum follow-up of 5 months.19/34 (55.9%) patients achieved DS ≤ 3 on PET-1, the remaini...
Source: Nuklearmedizin - April 9, 2024 Category: Radiology Authors: Christoph-Ferdinand Wielenberg Johannes Christian Fostitsch Christian Volz Reinhard Marks Kerstin Michalski Ralph W äsch Robert Zeiser Juri Ruf Philipp T Meyer Claudius Klein Source Type: research
FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL)
This study evaluates the role of fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) in NHL treated with CAR T-cell therapy concerning response assessment and prognosis.We evaluated 34 patients with NHL who received a CAR T-cell therapy between August 2019 and July 2022. All patients underwent a pre-therapeutic FDG-PET/CT (PET-0) 6 days prior and a post-therapeutic FDG-PET/CT (PET-1) 34 days after CAR T-cell therapy. Deauville score (DS) was used for evaluation of response to therapy and compared to a minimum follow-up of 5 months.19/34 (55.9%) patients achieved DS ≤ 3 on PET-1, the remaini...
Source: Nuklearmedizin - April 9, 2024 Category: Radiology Authors: Christoph-Ferdinand Wielenberg Johannes Christian Fostitsch Christian Volz Reinhard Marks Kerstin Michalski Ralph W äsch Robert Zeiser Juri Ruf Philipp T Meyer Claudius Klein Source Type: research
FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL)
This study evaluates the role of fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) in NHL treated with CAR T-cell therapy concerning response assessment and prognosis.We evaluated 34 patients with NHL who received a CAR T-cell therapy between August 2019 and July 2022. All patients underwent a pre-therapeutic FDG-PET/CT (PET-0) 6 days prior and a post-therapeutic FDG-PET/CT (PET-1) 34 days after CAR T-cell therapy. Deauville score (DS) was used for evaluation of response to therapy and compared to a minimum follow-up of 5 months.19/34 (55.9%) patients achieved DS ≤ 3 on PET-1, the remaini...
Source: Nuklearmedizin - April 9, 2024 Category: Radiology Authors: Christoph-Ferdinand Wielenberg Johannes Christian Fostitsch Christian Volz Reinhard Marks Kerstin Michalski Ralph W äsch Robert Zeiser Juri Ruf Philipp T Meyer Claudius Klein Source Type: research
FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL)
This study evaluates the role of fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) in NHL treated with CAR T-cell therapy concerning response assessment and prognosis.We evaluated 34 patients with NHL who received a CAR T-cell therapy between August 2019 and July 2022. All patients underwent a pre-therapeutic FDG-PET/CT (PET-0) 6 days prior and a post-therapeutic FDG-PET/CT (PET-1) 34 days after CAR T-cell therapy. Deauville score (DS) was used for evaluation of response to therapy and compared to a minimum follow-up of 5 months.19/34 (55.9%) patients achieved DS ≤ 3 on PET-1, the remaini...
Source: Nuklearmedizin - April 9, 2024 Category: Radiology Authors: Christoph-Ferdinand Wielenberg Johannes Christian Fostitsch Christian Volz Reinhard Marks Kerstin Michalski Ralph W äsch Robert Zeiser Juri Ruf Philipp T Meyer Claudius Klein Source Type: research
FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL)
This study evaluates the role of fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) in NHL treated with CAR T-cell therapy concerning response assessment and prognosis.We evaluated 34 patients with NHL who received a CAR T-cell therapy between August 2019 and July 2022. All patients underwent a pre-therapeutic FDG-PET/CT (PET-0) 6 days prior and a post-therapeutic FDG-PET/CT (PET-1) 34 days after CAR T-cell therapy. Deauville score (DS) was used for evaluation of response to therapy and compared to a minimum follow-up of 5 months.19/34 (55.9%) patients achieved DS ≤ 3 on PET-1, the remaini...
Source: Nuklearmedizin - April 9, 2024 Category: Radiology Authors: Christoph-Ferdinand Wielenberg Johannes Christian Fostitsch Christian Volz Reinhard Marks Kerstin Michalski Ralph W äsch Robert Zeiser Juri Ruf Philipp T Meyer Claudius Klein Source Type: research
FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL)
This study evaluates the role of fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) in NHL treated with CAR T-cell therapy concerning response assessment and prognosis.We evaluated 34 patients with NHL who received a CAR T-cell therapy between August 2019 and July 2022. All patients underwent a pre-therapeutic FDG-PET/CT (PET-0) 6 days prior and a post-therapeutic FDG-PET/CT (PET-1) 34 days after CAR T-cell therapy. Deauville score (DS) was used for evaluation of response to therapy and compared to a minimum follow-up of 5 months.19/34 (55.9%) patients achieved DS ≤ 3 on PET-1, the remaini...
Source: Nuklearmedizin - April 9, 2024 Category: Radiology Authors: Christoph-Ferdinand Wielenberg Johannes Christian Fostitsch Christian Volz Reinhard Marks Kerstin Michalski Ralph W äsch Robert Zeiser Juri Ruf Philipp T Meyer Claudius Klein Source Type: research
Burden of Infection in Patients With and Without Secondary Immunodeficiency Disease Following Diagnosis of a Mature B Cell Malignancy
Patients with mature B cell malignancies such as chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), multiple myeloma (MM), and non-Hodgkin's lymphoma (NHL) are at risk of developing secondary immunodeficiency disease (SID) owing to the underlying disease process and the use of anti-cancer treatments with immunosuppressive effects.1 Patients with mature B cell malignancies and SID are susceptible to severe, recurrent, or persistent infections that result in substantial morbidity and increased mortality, as well as a considerable economic burden. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 9, 2024 Category: Hematology Authors: Joshua Richter, Matthew S. Davids, Colin Anderson-Smits, Marta Kamieniak, Kaili Ren, Michael Hull, Jasjit K. Multani, Drishti Shah, Csaba Siffel Source Type: research
